Published : 10 May 2018
Aagami Inc. has been appointed to support its new California based client’s Next-Generation PEG technology and assets with 53 Patents. The Technology is already in the market with one asset utilizing the technology being sold in the US market.
Client’s Next-Generation PEGylation overcomes many limitations of mPEG and has several Clinical and Commercial Advantages. This Next-generation PEGylation technology is available for testing with a partner’s product candidates and for sale or license/ codevelopment. Also, several conjugates are available for partnering. Client is also open for broader opportunities..
Aagami will also be representing this client at the BIO 2018 International Convention in Jun 2018.
With 2 assignments in 2 days, Aagami is excited to contribute in its clients’ success.